Trump’s Pharma Tariff: India’s $50B Industry at a Global Crossroads

1. Context: U.S. Tariffs on Pharmaceutical Imports

In September 2025, the U.S. announced a 100% tariff on branded and patented pharmaceutical imports, effective from October 1, 2025. The measure aims to boost domestic manufacturing but poses significant challenges to global supply chains, particularly affecting India, often called the “pharmacy of the world.” India’s pharmaceutical sector, valued at $50billion\ast \ast andcontributing\ast \ast 1.72$9 billion in FY25, a 14.29% year-on-year increase. The tariffs target branded drugs but exclude generics, which form the bulk of India’s exports.

India’s position as a leading global supplier of generics provides a buffer against immediate shocks. However, dependency on imports, particularly $5 billion worth of active pharmaceutical ingredients (API) from China (72% share), exposes vulnerabilities. Policy measures such as GST rationalisation and domestic schemes offer partial mitigation.

The governance implication is that international trade policies can have a direct impact on domestic industrial growth and fiscal stability. Ignoring global supply chain vulnerabilities could lead to export revenue loss and slowed GDP growth.

• Key statistic:
  • India’s pharma exports to U.S.: $9 billion (FY25)
  • Contribution to global generic supply: 40% of U.S. generics
  • Potential GDP impact if tariffs escalate: 0.2%-0.3% reduction

2. Global Pharmaceutical Landscape

Global pharmaceutical trade, valued at $850billionin2024\ast \ast ,isdrivenbyagingpopulations,chronicdiseases,andpost-COVIDinnovations.LeadingexportersincludeGermany(\ast \ast$119.85 billion), Switzerland ($99.08billion\ast \ast ),andtheU.S.(\ast \ast$90.30 billion), while top importers include the U.S. ($212.67 billion), Switzerland, Germany, Belgium, and China. The EU exported €313.4 billion in 2024, a 13.5% increase over the previous year, reflecting resilience despite geopolitical tensions.

India ranks as the third-largest exporter by volume, shipping **$30.47billioninFY25\ast \ast ,upfrom$27 billion in 2023. Generics constitute 70% of exports to the U.S. and Europe, underscoring India’s strategic role in global healthcare affordability. However, reliance on imported APIs, mainly from China, creates a risk of supply chain disruption.

Maintaining a diversified export portfolio and strengthening domestic production are critical for industrial resilience. Neglecting global trade dynamics could limit India’s ability to leverage its generics sector in the international market.

• Global context:
  • EU medicinal exports 2024: €313.4 billion
  • India’s global rank by export volume: 3rd
  • Generics share in U.S. imports: 40%

3. Economic and Sectoral Implications for India

India’s pharmaceutical sector contributes significantly to GDP growth, foreign exchange reserves, and employment. The 10%-12% CAGR of the sector adds 0.5%-1% annually to GDP growth. Stocks of major pharma firms fell immediately after the U.S. tariff announcement, highlighting market sensitivity. Potential escalation to generics could reduce export revenue by 10%-15%, with ripple effects on GDP.

Tariff-induced disruptions also affect R&D investment, API inflation (5%-7%), and regulatory compliance costs. Some firms, with over 30% U.S. exposure, face challenges in rerouting exports, which may prompt “China-plus-one” strategies, targeting Africa and Southeast Asia. This could potentially increase India’s regulated market share from 3% to 3.5% by 2030.

Ensuring sectoral resilience through policy incentives, domestic production, and market diversification mitigates risks to national economic stability. Ignoring these could compromise India’s global competitiveness in pharmaceuticals.

• Impacts:
  • Export revenue risk: 10%-15%
  • GDP growth reduction risk: 0.2%-0.3%
  • API cost increase: 5%-7%
  • Market share potential in Africa: +0.5% by 2030

4. Domestic Policy Measures and Market Buffers

India’s Goods and Services Tax (GST) rationalisation, effective September 22, 2025, reduced drug and medicine rates from 12% to 5%, with 36 essential items at nil, saving $1.2billionannually\ast \ast .MedicaldevicessawGSTreductionfrom\ast \ast 18$5 billion. Pre-existing stocks were exempt from re-labelling, limiting disruptions.

Schemes such as Ayushman Bharat and PMBJP enhance affordability, with 16,912 Jan Aushadhi Kendras operational and 2,110 medicines plus 315 surgical/medical devices available. The PMBJP oncology basket reduces cancer treatment costs by 70%, cushioning domestic markets against international tariff shocks.

Proactive fiscal and healthcare policies stabilize domestic markets, ensuring access and affordability. Ignoring these buffers could amplify the socioeconomic impact of global trade policies.

• Policy measures:
  • GST rationalisation: drugs 12% → 5%, medical devices 18% → 5%
  • PMBJP centers: 16,912
  • Medicines under PMBJP: 2,110
  • Medical devices: 315

5. International Cooperation and Strategic Diversification

India’s pharmaceutical diplomacy includes MoUs with Trinidad and Tobago, an API pact with Singapore, and Serum Institute collaborations for low- and middle-income countries. Participation in iPHEX enables export expansion, especially to Africa, potentially offsetting 20%-25% of tariff risks.

Eastern alliances, particularly with China, dominate biotech deals (32% of global Q1 2025 deals) and molecule licensing ($2.5 billion U.S. agreements, H1 2025). EU-U.S. trade focuses on supply chain security. India’s strategy of east-west partnerships enhances resilience, mitigates tariff exposure, and promotes equitable global healthcare access.

Strategic diplomacy and trade diversification reduce dependency on any single market. Failing to leverage such alliances could constrain India’s export-led growth and global healthcare influence.

• Key partnerships:
  • 6 MoUs with Trinidad and Tobago (July 2025)
  • Singapore API agreement
  • Potential tariff risk offset: 20%-25%

6. Growth Prospects and Future Readiness

India’s pharmaceutical sector aims to reach $130billionby2030\ast \ast withan\ast \ast 11$120-$130billion\ast \ast .Globalspendingcouldhit\ast \ast$1.5 trillion by 2029, driven by biosimilars and precision medicine. India’s API sector could reach ₹1.82 trillion ($22 billion) by 2030, supported by PLI schemes, which aim to reclaim 20% domestic production.

Challenges remain, including IP disputes and API dependency. Yet, domestic initiatives like PMBJP and GST reforms, coupled with international collaborations, bolster resilience. Addressing these systematically ensures India remains a key player in global healthcare while safeguarding affordability for domestic populations.

Long-term strategic planning and investment in domestic capabilities, coupled with export diversification, secure India’s global leadership in pharmaceuticals. Neglecting growth planning may undermine economic and health objectives.

• Growth projections:
  • Market size 2030: $130 billion
  • Exports 2030: $120-$130 billion
  • API sector 2030: $22 billion
  • PLI domestic production target: 20%

7. Conclusion

India’s pharmaceutical sector faces a critical juncture due to U.S. tariffs. While generics and domestic policy buffers provide immediate resilience, long-term stability requires diversified trade partnerships, investment in APIs, and strategic international collaborations. A coordinated approach ensures economic growth, global competitiveness, and sustained healthcare affordability.

"Access to medicine is a right, not a privilege." — WHO

By integrating policy, diplomacy, and innovation, India can secure its position as the global pharmacy of the world while mitigating external shocks and supporting domestic healthcare objectives.